 phase II trial piritrexim metastat melanoma intermitt low-dos administr phase II trial piritrexim pyrido- pyrimidin ptx patient metastat malign melanoma intermitt low-dos oral administr schedul ptx dose mg time day day week week rest patient studi patient assess respons complet respons cr partial respons pr respons rate CR PR confid limit respons soft tissu lesion respons lung lesion initi dose schedul dose-limit toxic myelosuppress ptx schedul activ malign melanoma further clinic trial result underway